Celsius stock is down more than 70% from its all-time high as revenue plunges. Its market share continues to rise, however, which warrants a closer look at the overall health of this business. In ...
One major concern is the company’s underwhelming marketshare for its COVID vaccine, Nuvaxovid, which accounted for only about 3% of the market during a critical vaccine season. This limited ...